Coronary heart disease (CHD) is the single largest cause of death worldwide (1, 2).
Numerous risk factors influence the development and severity of CHD, such as hypercholesterolemia, smoking, hypertension and diabetes (3) . Several of these risk factors have a major heritable component, but the nature of the DNA sequence variations that confer cardiovascular risk remain largely unknown. Mutations responsible for Mendelian forms of hypercholesterolemia greatly increase the risk of coronary atherosclerosis, but these diseases account for only a small fraction of individuals with heart disease (4). Single nucleotide polymorphism (SNP) association studies (3) and genome-wide linkage scans have reported common alleles associated with CHD risk (5-10), but none has been validated by replication in multiple cohorts.
To identify sequence variants associated with CHD, we undertook a genome-wide association study using 100,000 SNPs. To minimize false positive associations, without unduly sacrificing statistical power, we used an iterative case-control design comprising three sequential comparisons between cases and controls that were performed at a nominal significance threshold of P<0.025 (Figure 1 ). Assuming independence, the probability of any single SNP achieving this level of significance in all three studies with the associations being in the same direction was 3.9 X 10 -6 (0.025 3 X 0.5 2 ). Thus, none of the 100,000 SNPs would be expected by chance to replicate consistently in all three comparisons. For the initial genome-wide scan, cases and controls were white men and women recruited from Ottawa, Canada to participate in the Ottawa Heart Study (OHS). Cases had symptomatic CHD with documented onset before the age of 60 years and culminating in coronary artery revascularization (bypass grafting or percutaneous coronary intervention). To limit confounding by known major risk factors that strongly predispose to premature CHD, individuals with diabetes, or with plasma cholesterol levels consistent with monogenic hypercholesterolemia (>280 mg/dL) were excluded. Controls were healthy white men (>65 y) and women (>70 y) recruited at the same institution as the cases who had no symptoms or history of CHD.
Custom oligonucleotide arrays (11) were used to assay 100,000 SNPs arranged at approximately 30 kb intervals throughout the genome in 322 cases and 312 controls (OHS-1).
Of these, 9,636 SNPs deviated strongly from Hardy-Weinberg equilibrium (P<0.001) or did not meet quality-control criteria (11) and 17,500 were sub-polymorphic (minor allele frequency <1%) in the sample. The remaining 72,864 SNPs were entered into the analysis and 2,586 were associated with CHD in OHS-1 at a nominal significance threshold of 0.025 (Table 1) . These 2,586 SNPs were genotyped in a second group of 311 cases and 326 controls (OHS-2), selected from the same population using the same criteria as OHS-1. Of these, 50 were associated with CHD at a nominal significance threshold of 0.025, with the same direction of effect.
To limit attrition of true positive associations due to inadequate statistical power, the third case-control comparison was performed in the Atherosclerosis Risk in Communities (ARIC) study, a large prospective study of CHD risk that enrolled and followed 11,478
European-Americans (12) . For this analysis, cases were defined as individuals with a documented CHD event (defined as myocardial infarction, coronary artery revascularization, or coronary death) during the 15 yr follow-up period of the study; individuals with prevalent disease at the baseline visit were excluded. The study sample delineated by these criteria provides > 90% power to detect common alleles (minor allele frequency >0.1) that differ in frequency by 0.06 or more between cases and controls. Nonetheless, only two of the 50 SNPs identified in the Ottawa cohorts were significantly associated with incident CHD in the ARIC population (Table 1) . These two SNPs, rs10757274 and rs2383206, were located within 20 kb of each other on chromosome 9 and were in strong linkage disequilibrium (r 2 =0.89). Both
SNPs involve the substitution of G for A. At both loci the A and G alleles were present at almost equal frequencies among the controls in the three samples. The presence of a G allele was associated with an increased risk of CHD in all three groups (OHS-1, OHS-2, and ARIC) ( Table 2) .
To validate the association between rs10757274 and rs2383206 and CHD, both SNPs were assayed in three additional independent cohorts: the Copenhagen City Heart Study (CCHS), a prospective study of ischemic heart disease in 10,578 Danish men and women (13) ; the Dallas Heart Study (DHS), a population-based probability sample of Dallas County residents (14) ; and a third group of 647 cases and 847 controls from the Ottawa Heart Study population who had not been included in the genome-wide scan or in the first replicate analysis (OHS-3). In the CCHS, cases were individuals who experienced an ischemic cardiovascular event during the 20 yr follow-up period while controls were those who did not develop incident disease. In the DHS, electron-beam computer tomography was used to measure coronary artery calcium (CAC), an index of coronary atherosclerosis (15) . Each individual underwent two consecutive scans. The distribution of CAC scores is extremely skewed and inter-scan variability is high for scores below 10 Agatston units (16), therefore we excluded individuals with CAC scores between 2 and 10 units and divided the population into controls (CAC scores of ≤ 2 units, n=575) and cases (those with CAC scores ≥10 units, n=166), as previously described (16) . In OHS-3, cases had documented CHD before the age of 55 (men) or 65 (women), whereas controls were men and women aged > 70 years who did not have symptoms of CHD. In all three validation studies, both SNPs were significantly associated with CHD (Table 2 ). These data further support the association between the G alleles of rs10757274 and rs2383206 and CHD.
The magnitude of incident CHD associated with the G allele was determined by Cox proportional-hazards modeling in the ARIC and CCHS cohorts. The hazard ratios associated with the risk alleles were comparable in the two populations, and indicated a graded increase in risk from noncarriers to heterozygotes to homozygotes ( Tables 1 and 2 ). The risk allele was associated with a slight but statistically significant decrease in body mass index in the ARIC cohort, but not in the CCHS population.
Thus, the effect of the chromosome 9 risk allele on CHD is not mediated by any of the established major risk factors for the disease. contain open reading frames that extend more than a few amino acids. As a first step towards identifying functional elements responsible for the observed association, we sequenced the 58 kb interval in two homozygotes for the risk allele, and in one individual who was homozygous for the reference allele. Of the 66 polymorphisms (SNPs plus small insertions or deletions) identified in the 6 alleles that were sequenced, 35 were specific to the risk allele (Supplementary Table 3 ). Only one of these variants, a copy number variation in a run of 9
consecutive CAT repeats (extending from nucleotide 22110787 to 22110814, NCBI build 36.1) mapped to a spliced transcript (BI765545) that appears to be part of a large noncoding RNA, DQ485453 (17) . PCR amplification of cDNAs confirmed expression of the transcript in placenta and transformed lymphocytes (data not shown). Whereas the function of DQ485453 is not known, it is possible that variation in the expression or function of this transcript may be associated with risk of CHD.
Alternatively the risk allele may alter the sequence of a regulatory element that affects the expression of a gene(s) located outside of the 58 kb interval. Cross-species sequence alignments using VISTA revealed several segments within the 58 kb interval that are conserved among humans, dogs and mice that may contain such regulatory elements (Supplementary Figure 1) . It is also possible that the risk allele extends beyond the 58 kb interval defined in this study, and that the functional sequence variants that confer risk of CHD are located outside of the interval. Resequencing the coding regions of the two genes most proximal to the risk locus, CDKN2A and CDKN2B, which lie 70-100 kb telomeric to the interval (Figure 2 ), revealed only a single variant (A158S in CDKN2A) that was present in 6 of the 96 apparently healthy white men and women examined. The localization of the risk locus to a region devoid of known genes implicates a previously unrecognized gene that can substantially affect CHD risk independently of the established CHD risk factors. Further studies will be required to elucidate the mechanism by which allelic variation at the locus modulates risk of coronary heart disease.
The greater haplotype diversity found in populations of African descent (18) Table 4 ).
Of the 10 alleles that were significantly associated with CHD in whites, 3 were virtually absent from the Yoruba population, and 6 others significantly less common. Both rs10757274 and rs2383206 were present at appreciable frequencies among AfricanAmericans in ARIC and DHS, but neither SNP was associated with CHD in either population (Supplementary Table 5 ). It is possible that the apparent ethnic differences in association between these SNPs and CHD in ARIC are a spurious consequence of differences statistical power: there are significantly fewer African-Americans than whites in the ARIC study.
However inadequate statistical power cannot explain the ethnic differences observed in DHS, since African-Americans are the largest group in this study. Accordingly, it seems more likely that the functional sequence variants associated with the risk allele in whites are less common in African-Americans. This notion is consistent with our finding that the frequencies of several alleles associated with CHD risk factors differ widely between these ethnic groups (19) (20) (21) . Comprehensive analysis of the locus in African-Africans may allow further refinement of the risk interval.
The results of this study illustrate both the perils and the promise of whole-genome association. The initial scan and the first replicate screen both generated substantially more
SNPs that achieved the pre-specified significance threshold than would be predicted by chance alone, as indicated by permutation testing. Yet only two of these SNPs (comprising one allele) survived further replication, despite the use of a large sample (i.e. ARIC) with high statistical power. This finding highlights the necessity for adequate replication to protect against artifacts that may occur due to population stratification, multiple testing, or other factors to which whole-genome association studies are particularly susceptible. The consistent replication of the chromosome 9 risk allele in six independent study samples indicates that the approach can be productively applied to conditions as complex as CHD, which is known to be influenced by a variety of environmental and genetic factors (22).
Analysis of 50 randomly selected regions of 500 kb each indicated that the 72,864
informative SNPs used in the initial scan provided 30-40% of the power that would be obtained by assaying all Phase II Hapmap SNPs. Therefore scans with denser SNP panels may reveal further loci associated with CHD risk. The mean age of the control subjects was 74.9+4.8(SD) years.
2) The Atherosclerosis Risk in Communities Study (ARIC). The ARIC study comprised men and women aged 45 to 64 years who were randomly selected from four communities (Jackson, MS; Minneapolis MN; Forsyth County, NC; and Washington County, MD). Race or ethnic group was determined by self-identification; participants described themselves as black or white in response to a questionnaire on which the available categories were "black", "white", "Indian", or "Asian". Plasma lipids, glucose, insulin and lipoproteins were assayed in the ARIC central lipid laboratory with commercial reagents, as previously described 1-3 .
3) The Copenhagen City Heart Study (CCHS). The Copenhagen City Heart Study population was randomly drawn from the Copenhagen Population Register in January 1976 4 . The sample was drawn from a population of approximately 90 000 inhabitants 20 years and older living within 10 wards surrounding Rigshospitalet, the National University Hospital of Copenhagen.
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A second examination was performed 5 years later (1981) (1982) (1983) , and a third examination was performed after 15 years (1991-1994) , at which time blood samples were obtained from 9,259 individuals for isolation of DNA. A self-administered questionnaire was used to obtain information regarding familial history, education and socio-economic status, and smoking and drinking habits. Plasma cholesterol and triglyceride levels were determined enzymatically using commercial reagents, and HDL-C was determined after removal of apoB-containing lipoproteins by precipitation with phosphotungstic acid and magnesium.
Participants were white and of Danish descent.
4) The Dallas Heart Study. The Dallas Heart Study is a multi-ethnic, population-based probability sample of Dallas County residents. The study included three phases: an in-home interview, an in-home phlebotomy visit, and a clinic visit during which a variety of imaging examinations were performed. White men and women who underwent electron-beam computer tomography to assess coronary artery calcification were eligible for the present study.
Genotyping:
1) Oligonucleotide hybridization. A total of 100,000 sequence variants spavced at * kb intervals across the genome were assayed by hybridization to oligonucleotides arrays synthesized on glass slides as described 5 . Briefly, each SNP was interrogated by 24 25mer oligonucleotide probes targeting both the reference and alternate alleles on forward and reverse strands. Each allele and strand was represented by six oligonucleotides comprising five perfect match probes and one mismatch.
2) Mass Spectrometry. The 50 sequence variants identified in the genome-wide scan were assayed in the ARIC population by mass spectrometry using the Sequenom MassARRAY system (Sequenom, Inc.; San Diego, CA).
3) Fluorogenic 5'-nucleotidase assays for rs10757274 and rs2383206 were developed with the use of the TaqMan assay system (Applied Biosystems). The assays were performed on a 7900HT Fast Real-Time PCR instrument with probes and reagents purchased from Applied Biosystems.
DNA sequencing. The 58 kb interval between rs12555547 and rs10965244 was sequenced in two individuals homozygous for the risk allele, and in one individual homozygous for the wild-type allele as described 6 . The coding region and flanking intronic sequences of CDKN2A and CDKN2B were sequenced in 96 healthy white men. All sequence variants identified were verified by manual inspection of the chromatograms and missense changes were confirmed by an independent resequencing reaction.
Reverse transcription and PCR Amplification of cDNAs. RNA was isolated from human brain, liver, placenta, and lymphocytes by a modified phenol-chloroform extraction (TRIZOL reagent, Invitrogen Corporation, Carlsbad, CA), and reverse transcribed (SuperScript III First-strand synthesis system, Invitrogen). Aliquots of cDNA were amplified using primers directed against spliced ESTs CN277071, BX100299 and DQ485453. Primer sequences are available from the authors upon request.
Statistical Analysis. For the genome-wide scan, allelic associations were evaluated for each SNP using chi-square tests on 2×2 contingency tables with no adjustments. Calculations were performed independently at Perlegen Sciences and at UT Southwestern and essentially identical results were obtained. To determine the empirical P-values we randomized the sample case/control status 1,000 times, and calculated allelic associations on each permuted dataset. SNPs that were significantly associated with CHD in the genome-wide scan were assayed in a second set of cases and controls and analyzed using Chi-square tests and permutation testing. For the remaining data sets, case-control differences in allele frequencies of rs10757274 and rs2383206 were evaluated using chi-square tests on 3X2 Values are means ± standard deviations, except for triglycerides which are medians (interquartile ranges). P-values were calculated using ANOVA. Variables with highly skewed distributions (triglycerides) were log transformed prior to analysis. Values are means ± standard deviations, except for triglycerides which are medians (interquartile ranges). P-values were calculated using ANOVA. Variables with highly skewed distributions (triglycerides) were log transformed prior to analysis.
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